Genomic and RT-qPCR analysis of trimethoprim-sulfamethoxazole and meropenem resistance in Burkholderia pseudomallei clinical isolates.

Autor:	Schnetterle M; Bacteriology Unit, UMR-MD1 INSERM 1261, French Armed Biomedical Research Institut, Brétigny-sur-Orge, France.; Ecole du Val de Grace, Paris, France., Gorgé O; Bacteriology Unit, UMR-MD1 INSERM 1261, French Armed Biomedical Research Institut, Brétigny-sur-Orge, France., Nolent F; Bacteriology Unit, UMR-MD1 INSERM 1261, French Armed Biomedical Research Institut, Brétigny-sur-Orge, France., Boughammoura A; Bacteriology Unit, UMR-MD1 INSERM 1261, French Armed Biomedical Research Institut, Brétigny-sur-Orge, France., Sarilar V; Molecular Biology Unit, French Armed Biomedical Research Institut, Brétigny-sur-Orge, France., Vigier C; Bacteriology Unit, UMR-MD1 INSERM 1261, French Armed Biomedical Research Institut, Brétigny-sur-Orge, France., Guillier S; Bacteriology Unit, UMR-MD1 INSERM 1261, French Armed Biomedical Research Institut, Brétigny-sur-Orge, France., Koch L; Bacteriology Unit, UMR-MD1 INSERM 1261, French Armed Biomedical Research Institut, Brétigny-sur-Orge, France.; Ecole du Val de Grace, Paris, France., Degand N; Laboratoire de bactériologie, Hôpital de l'Archet, Centre Hospitalier Universitaire de Nice, Nice, France., Ramisse V; DGA MNRBC- Le Bouchet, Division Biologie, ABIO, Vert-le-Petit, France., Tichadou X; DGA MNRBC- Le Bouchet, Division Biologie, ABIO, Vert-le-Petit, France., Girleanu M; Imagery Unit, Departement of plateforms and technology research, French Armed Biomedical Research Institut, Brétigny-sur-Orge, France., Favier AL; Imagery Unit, Departement of plateforms and technology research, French Armed Biomedical Research Institut, Brétigny-sur-Orge, France., Valade E; Bacteriology Unit, UMR-MD1 INSERM 1261, French Armed Biomedical Research Institut, Brétigny-sur-Orge, France.; Ecole du Val de Grace, Paris, France., Biot F; Bacteriology Unit, UMR-MD1 INSERM 1261, French Armed Biomedical Research Institut, Brétigny-sur-Orge, France., Neulat-Ripoll F; Bacteriology Unit, UMR-MD1 INSERM 1261, French Armed Biomedical Research Institut, Brétigny-sur-Orge, France.
Jazyk:	angličtina
Zdroj:	PLoS neglected tropical diseases [PLoS Negl Trop Dis] 2021 Feb 16; Vol. 15 (2), pp. e0008913. Date of Electronic Publication: 2021 Feb 16 (Print Publication: 2021).
DOI:	10.1371/journal.pntd.0008913
Abstrakt:	Background: Melioidosis is an endemic disease in southeast Asia and northern Australia caused by the saprophytic bacteria Burkholderia pseudomallei, with a high mortality rate. The clinical presentation is multifaceted, with symptoms ranging from acute septicemia to multiple chronic abscesses. Here, we report a chronic case of melioidosis in a patient who lived in Malaysia in the 70s and was suspected of contracting tuberculosis. Approximately 40 years later, in 2014, he was diagnosed with pauci-symptomatic melioidosis during a routine examination. Four strains were isolated from a single sample. They showed divergent morphotypes and divergent antibiotic susceptibility, with some strains showing resistance to trimethoprim-sulfamethoxazole and fluoroquinolones. In 2016, clinical samples were still positive for B. pseudomallei, and only one type of strain, showing atypical resistance to meropenem, was isolated. Principal Findings: We performed whole genome sequencing and RT-qPCR analysis on the strains isolated during this study to gain further insights into their differences. We thus identified two types of resistance mechanisms in these clinical strains. The first one was an adaptive and transient mechanism that disappeared during the course of laboratory sub-cultures; the second was a mutation in the efflux pump regulator amrR, associated with the overexpression of the related transporter. Conclusion: The development of such mechanisms may have a clinical impact on antibiotic treatment. Indeed, their transient nature could lead to an undiagnosed resistance. Efflux overexpression due to mutation leads to an important multiple resistance, reducing the effectiveness of antibiotics during treatment. Competing Interests: The authors have declared that no competing interests exist.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu PDF